Literature DB >> 31066490

Incidence, risk factors, and outcomes of warfarin-associated major bleeding in Thai population.

Watcharapong Priksri1, Wipharak Rattanavipanon2, Wiwat Saejear3, Krittika Tanyasaensook2, Arintaya Phrommintikul4, Suvatna Chulavatnatol2, Surakit Nathisuwan2.   

Abstract

PURPOSE: This study aimed to describe incidence, risk factors, and outcomes of warfarin-associated major bleeding (WAMB) in Thai patients.
METHOD: A nested case-control study was conducted in a cohort of adult patients receiving ≥6 months of warfarin therapy who were prospectively followed up at a tertiary care hospital in Thailand during January 2011 to December 2014. Logistic regression was used to identify risk factors associated with WAMB. The area under the receiver operating characteristic (AUROC) curve was used to assess the performance of the HAS-BLED score to predict WAMB in patients with non-valvular atrial fibrillation (NVAF).
RESULTS: Among 1604 patients (2972 patient-year of follow-up), there were 93 major bleeding that occurred in 76 patients. The incidence of WAMB was 3.13 events per 100 patient-year. Time in therapeutic range (TTR) of <60% (RR: 3.62, 95% CI: 1.94-6.73, P < 0.001), mechanical valve replacement at mitral position (RR 3.43, 95% CI: 1.92-6.16, P < 0.001) cancer (RR: 2.84, 95% CI: 1.11-7.29, P = 0.029), and age ≥ 65 years (RR: 2.37, 95% CI: 1.20-4.67, P = 0.012) were independent risk factors for WAMB. There were 17 fatalities and 12 cases of disabilities from WAMB. Mean cost of WAMB was 45 341.54 THB/event. An exploratory analysis suggested that HASBLED score demonstrated an excellent discriminatory capacity to predict WAMB among NVAF patients (AUROC of 0.91, 95% CI: 0.85-0.97, P < 0.001).
CONCLUSION: WAMB in Thai population is common and associated with high rate of morbidity and mortality. Improvement in anticoagulation control is clearly needed.
© 2019 John Wiley & Sons, Ltd.

Entities:  

Keywords:  major bleeding; pharmacoepidemiology; vitamin K antagonist; warfarin

Mesh:

Substances:

Year:  2019        PMID: 31066490     DOI: 10.1002/pds.4781

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  2 in total

1.  Severity and Hospitalization Cost Related to Warfarin-Related Adverse Events in a Tertiary Malaysian Hospital.

Authors:  Doris George; Chung Aun Wong; Subramaniam Thanimalai; Hoo Seng Tan
Journal:  Hosp Pharm       Date:  2022-03-03

2.  Prospective randomised trial examining the impact of an educational intervention versus usual care on anticoagulation therapy control based on an SAMe-TT2R2 score-guided strategy in anticoagulant-naïve Thai patients with atrial fibrillation (TREATS-AF): a study protocol.

Authors:  Arintaya Phrommintikul; Surakit Nathisuwan; Siriluck Gunaparn; Rungroj Krittayaphong; Wanwarang Wongcharoen; Sukhi Sehmi; Samir Mehta; Neil Winkles; Peter Brocklehurst; Jonathan Mathers; Sue Jowett; Kate Jolly; Deirdre Lane; G Neil Thomas; Gregory Y H Lip
Journal:  BMJ Open       Date:  2021-10-11       Impact factor: 2.692

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.